Protein-protein interactions in human disease. Part B /

• Άλλοι συγγραφείς: Donev, Rossen (Επιμελητής έκδοσης)
• Μορφή: Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Cambridge, MA : Academic Press is an imprint of Elsevier, 2018.
• Έκδοση: First edition.
• Σειρά: Advances in protein chemistry and structural biology ; v. 111.
• Θέματα: Protein-protein interactions.; SCIENCE > Chemistry > Organic.; Electronic books.

Πίνακας περιεχομένων:

• Front Cover; Protein-Protein Interactions in Human Disease, Part B; Copyright; Contents; Contributors; Preface; Chapter One: Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design; 1. Introduction; 2. Methods to Study PPIs and Their Inhibition; 2.1. Coimmunoprecipitation; 2.2. Pull-Down Assay; 2.3. Proximity Ligation Assay; 2.4. Enzyme Fragment Complementation Assay (PathHunter Assay); 2.5. Surface Plasmon Resonance; 2.6. Mutational Studies to Identify Hot Spots in PPI; 3. Inhibition of Dimerization of Protein and PPI.
• 4. Design of Compounds Based on Protein Interface4.1. Structure-Based Drug Design; 4.2. Fragment-Based Discovery in PPI Inhibition; 4.3. High-Throughput Screening; 5. Homodimers; 5.1. G-Protein-Coupled Receptors; 5.2. Receptor Tyrosine Kinase-Like Orphan Receptor 2; 5.3. Glucocorticoid Receptor; 5.4. Amyloid Precursor Protein Dimers; 5.5. EGFR Homodimers; 6. Heterodimerization of Proteins and Inhibition; 6.1. p45-p75 Heterodimers; 6.2. IL-6-IL-6Rα; 6.3. Epidermal Growth Factor Receptors; 6.3.1. Structure of ECDs of Proteins; 6.3.2. Design Concept; 6.4. PD-1-PD-L1 Pathway; 6.5. CD-28/CD-80.
• 6.6. CD2-CD58 Interactions and the Design of Multicyclic Peptides6.6.1. Multicyclic Peptide Approach; References; Chapter Two: Targeting Intramembrane Protein-Protein Interactions: Novel Therapeutic Strategy of Millions Years Old; 1. Introduction; 2. PPIs in Transmembrane Signaling; 2.1. Intramembrane and Cytoplasmic Interactions; 2.1.1. Single-Chain Receptors; 2.1.2. Multichain Receptors; 2.2. Transmembrane Signaling and Viral Evasion Strategies: Evolutionary and Molecular Aspects; 3. Intramembrane PPIs as a Therapeutic Target; 3.1. Cancer; 3.1.1. Nonsmall Cell Lung Cancer.
• 3.1.2. Pancreatic Cancer3.2. Autoimmune Diseases; 3.2.1. Targeting T Cell Receptor; 3.2.2. Targeting TREM-1; 3.3. Sepsis; 3.4. Thrombosis; 3.5. Retinopathy; 4. Conclusions; Acknowledgments; References; Further Reading; Chapter Three: Targeting the Architecture of Deregulated Protein Complexes in Cancer; 1. Introduction; 2. RAS:RAF Signalosome and Network; 2.1. Background; 2.2. Small G Proteins of the RAS Family and RAF Family Serine-Threonine Kinases; 2.3. Physiological and Pathophysiological Functions; 2.4. Pharmacological Targeting of RAS:RAF Complexes; 3. PKA Signalosome and Network.
• 3.1. Background3.2. Macromolecular PKA Complexes; 3.3. Pathological PKA Functions; 3.4. Pharmacological Targeting of PKA Emanating PPIs; 4. MYC:MAX Signalosome and Network; 4.1. The MYC:MAX Network; 4.2. Physiological and Oncogenic Functions; 4.3. Pharmacological Interference; 5. Conclusions; Acknowledgments; References; Chapter Four: Multifaceted Nucleolin Protein and Its Molecular Partners in Oncogenesis; 1. Introduction; 2. Structure of Nucleolin; 3. Role of Nucleolin in Ribosome Biogenesis and Gene Expression in Cancer Cells; 4. Functions of Nucleolin in DNA Repair and Genome Stability.